Resources

Resources

CEO Council for Growth and IntegriChain Sponsor Educational Webinar Series for Emerging Cell & Gene Therapy Companies

CEO Council for Growth’s Cell & Gene Therapy and Connected Health Initiative, in partnership with IntegriChain, is pleased to announce a three-part educational webinar series designed specifically for emerging cell and gene therapy (CGT) firms. The focus will be on launch and commercialization preparedness.

Discovery and development are necessarily the focus during the earliest stages of development of CGTs, but careful market access plans are also essential if a therapeutic is to reach as many patients as possible. To support young companies and stimulate overall industry growth in this important subsector of the life sciences, experts from Philadelphia-based IntegriChain, a data and business process platform for therapy commercialization and access, will share their knowledge and experiences via this complimentary educational series running Summer 2020.

     

    Launch Readiness for Cell & Gene Therapies in the Government & Commercial Channels

    June 25, 2020
    1:00 PM
    Register Here.

    Readying for the Government and Commercial Channels is an important launch preparedness step for CGT companies. This webinar from IntegriChain expert Jeff Baab will present crucial contracts and pricing timelines and milestones to get contracts in place for Day 1 readiness. Additional topics to be explored include: 

    • Basic of contracting strategies
    • Key considerations for launch readiness

    Who should attend: Finance, Pricing and Contracting professionals


    Contracting Implications for Cell & Gene Therapies

    July 16, 2020
    1:00 PM
    Register Here.

    Cell and Gene Therapy companies have unique pricing and contracting strategies that can impact government program access. Join IntegriChain’s Jeff Baab and Josef Magpantay as the do a “deep-dive” into contracting strategies and considerations. Topics to be explored include:

    • Key market considerations, such as payer coverage and policy trends
    • Techniques to maximize access to government and commercial channels
    • How coverage may change over time

    Along with key market access considerations — such as payer coverage and policy trends — to maximize access to government and commercial channels.

    Who should attend: Finance and Accounting Professionals, Contracting & Pricing Professionals, Market Access Executive Leadership


    Gross-to-Net Launch Readiness for Cell & Gene Therapies

    August 20, 2020
    1:00 PM
    Register Here.

    CGT companies seeking to maximize success for newly launched therapies understand that Gross-to-Net (GTN) – when done right – can improve patient access to therapies while driving revenues. This webinar focuses on mission-critical GTN activities for cell and gene therapy companies planning for commercial launch. IntegriChain experts Jeff Baab and Jen Sharpe will present a comprehensive countdown of the key GTN milestones your team must hit as you prepare for launch along with other important processes to maximize success, including:

    • Product pricing decisions and quantifying your payer mix
    • Modeling your co-pay program impact and understanding coverage gap liability
    • Meeting key government program enrollment deadlines
    • Employing best practices for forecasting and accrual management model development
    • Benchmarking via the Revenue Analytics Collaborative, a private online community of business and financial professionals 

    Who should attend: Finance and Accounting Professionals, Contracting & Pricing Professionals, Market Access Executive Leadership

    adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand